Marinomed Biotech

Bewertungs-Analyse

Über das Unternehmen

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company's products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marin

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Marinomed Biotech kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.